Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 04, 2022 16:29 ET
|
Olema Oncology
SAN FRANCISCO, Oct. 04, 2022 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema,” “Olema Oncology” or the “Company,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the...
Olema Oncology to Present at H.C. Wainwright 24th Annual Global Investment Conference
September 06, 2022 16:30 ET
|
Olema Oncology
SAN FRANCISCO, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema,” “Olema Oncology” or the “Company,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the...
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 01, 2022 17:01 ET
|
Olema Oncology
SAN FRANCISCO, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema,” “Olema Oncology” or the “Company,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the...
Olema Oncology Reports Second Quarter 2022 Financial Results and Provides Corporate Update
August 09, 2022 16:35 ET
|
Olema Oncology
Received Fast Track designation from U.S. FDA for OP-1250 for the treatment of ER+/HER2- metastatic breast cancerReported progress across OP-1250 clinical development program, including selection of...
Olema Oncology Advances OP-1250 into Phase 2 Monotherapy Expansion in Patients with ER+/HER2- Advanced Breast Cancer
August 09, 2022 16:30 ET
|
Olema Oncology
SAN FRANCISCO, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA), today announced the advancement of OP-1250, a complete estrogen receptor...
Olema Oncology to Present at Canaccord Genuity 42nd Annual Growth Conference
August 04, 2022 16:30 ET
|
Olema Oncology
SAN FRANCISCO, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery,...
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 03, 2022 16:30 ET
|
Olema Oncology
SAN FRANCISCO, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema,” “Olema Oncology” or the “Company,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the...
Olema Oncology Receives FDA Fast Track Designation for OP-1250 for the Treatment of ER+ / HER2- Metastatic Breast Cancer
July 21, 2022 07:30 ET
|
Olema Oncology
SAN FRANCISCO, July 21, 2022 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA) today announced that the U.S. Food and Drug Administration (FDA) has granted...
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 05, 2022 16:30 ET
|
Olema Oncology
SAN FRANCISCO, July 05, 2022 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema,” “Olema Oncology” or the “Company,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the...
Olema Oncology Provides Clinical Update Reflecting Strong Progress Across OP-1250 Development Program
June 09, 2022 07:35 ET
|
Olema Oncology
Favorable tolerability with no grade 3/4 neutropenia and encouraging anti-tumor activity across Phase 1b monotherapy expansionCombinability with CDK4/6i palbociclib demonstrated across initial dose...